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Background: Central neurocytoma was initially believed to be benign tumor type, although atypical 
cases with more aggressive behavior have been reported. Preoperative estimation for proliferating 
activity of central neurocytoma is one of the most important considerations for determining tumor 
management. 
Purpose: To investigate predictive values of image characteristics and quantitative measurements of 
minimum apparent diffusion coefficient (ADCmin) and maximum standardized uptake value 
(SUVmax) for proliferative activity of central neurocytoma measured by MIB-1 labeling index (LI). 
Material and Methods: Twelve cases of central neurocytoma including one recurrence from 
January 2001 to December 2011 were included. Preoperative scans were conducted in eleven, nine 
and five patients for computed tomography (CT), diffusion-weighted imaging (DWI) and 
fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET), respectively, and 
ADCmin and SUVmax of the tumors were measured. Image characteristics were investigated using 
CT, T2WI and contrast-enhanced T1WI, and their differences were examined using the Fisher’s 
exact test between cases with MIB-1 LI below and above 2%, which is recognized as typical and 
atypical central neurocytoma, respectively. Correlational analysis was conducted for ADCmin and 
SUVmax with MIB-1 LI. A P value < .05 was considered significant.  
Results: Morphological appearances had large variety, and there was no significant correlation with 
MIB-1 LI except a tendency that strong enhancement was observed in central neurocytomas with 
higher MIB-1 LI (P = 0.061). High linearity with MIB-1 LI was observed in ADCmin and SUVmax 
(r = -0.91 and 0.74, respectively), but only ADCmin was statistically significant (P = 0.0006).  
Conclusion: Central neurocytoma had a wide variety of image appearance, and assessment of 
proliferative potential was considered difficult only by morphological aspects. ADCmin was 









Central neurocytoma is a rare low grade tumor of the central nervous system, which was first 
described by Hassoun et al. in 1982 (1). It is composed of uniform round cells with neuronal 
differentiation constituting approximately 0.25 to 0.5% of all intracranial tumors. It occurs typically 
in young adults and is located in the lateral or third ventricle around the foramen of Monro (2). 
Clinical course of the central neurocytoma was initially believed to be benign, however, more 
aggressive behavior including rapid tumor progression, recurrence, extra-ventricular extension and 
craniospinal dissemination has been described (3, 4). The term atypical central neurocytoma has been 
proposed for an aggressive variant of the central neurocytoma, which is classified if MIB-1 
(Immunotech, Marseilles, France) labeling index (LI), an index of cellular proliferation, is higher 
than 2% (5) or atypical histologic features of focal necrosis, vascular proliferation and increased 
mitotic activity are observed (6). MIB-1 is a monoclonal antibody to Ki-67 antigen that is a nuclear 
protein associated with cellular proliferation.  
For patients with the atypical central neurocytoma, complete resection is the best treatment 
for better local control and survival (7). Therefore, preoperative estimation for proliferating activity 
of the central neurocytoma is one of the most important considerations for determining the 
appropriate surgical strategy. There are some reports discussing imaging features of the central 
neurocytoma. They reported varying degrees of contrast enhancement with or without cystic 
appearance and calcification of tumors (8, 9), but mainly focused on differentiating neurocytomas 
from other intraventricular tumors, and relationship between proliferative potential and 
morphological image findings has not been clarified. 
As quantitative imaging marker of malignancy, diffusion weighted imaging (DWI) provides 
further physiologic information as apparent diffusion coefficient (ADC), which is helpful in grading 
brain tumors (10, 11) including central neurocytoma (12). ADC correlates with tumor cellularity, 
prognosis and MIB-1 LI in gliomas (13-15). Other than MRI, standardized uptake value (SUV) 
measured by 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) reflects increased 
glucose metabolism and correlates with histological grade of gliomas (16). Mineura et al. reported 
rapid regrowth of central neurocytoma that had increased cerebral metabolic rate of glucose (17). 
Ohtani et al. reported a case of central neurocytoma with intense FDG uptake, which had a high 
MIB-1 LI and atypical pathological features (18). These cases indicate that SUV may also predict the 
proliferation potential of the central neurocytoma. However, preoperative estimation of the 
proliferative activity of the central neurocytoma has not been conducted. 
Therefore in this study, we investigated if image characteristics and quantitative values of 
ADC and SUV could distinguish central neurocytomas with MIB-1 LI higher than 2% from those 
with lower values. 
 
Material and Methods 
This study was approved by institutional review board, and informed consent was waived, because 
retrospective analysis was conducted.  
 
Patients 
Eleven patients from January 2001 to December 2011 at our institute were enrolled. Inclusion criteria 
was pathological confirmation of central neurocytoma and presence of preoperative imaging studies 
(CT, MRI and FDG-PET). There was one recurrent case at 3 years after partial tumor resection 
(patient 4 in Table 1). This case was enrolled as patient 4’, and images just before secondary 
operation were also analyzed.  
 
CT imaging 
CT images were obtained parallel to the orbitomeatal line. Resolutions of all CT images were 0.4 × 
0.4 × 7 - 8 mm.  
 
MR imaging 
MR scans were conducted with 1.5T scanners for 6 patients (patients 1, 3, 4, 4’ and 6 with 
MAGNETOM Symphony, Siemens Medical Systems, Erlangen, Germany; patients 2 and 5 with 
Signa Genesis, GE Healthcare, Milwaukee, WI, USA) and 3T scanners for 5 patients (patients 7, 8 
and 9 with MAGNETOM Trio; patients 10 and 11 with MAGNETOM Skyra, Siemens Medical 
Systems, Erlangen, Germany). In addition to conventional axial T1WI (TR/TE = 450 - 616/8.1 - 12 
ms) and T2WI (TR/TE = 3180 - 7960/93 - 130 ms), contrast-enhanced axial T1WI were acquired 
after administration of the Gadolinium contrast agent (0.1 mmol/kg) in 11 cases. DWI was acquired 
in 9 cases with in-plane resolution = 0.69 - 1.38 mm and slice thickness/spacing = 3 - 5/1 - 1.5 mm 
using a single-shot echo-planar sequence with motion-probing gradients (b = 0, 1000 s/mm2) applied 
in 3 orthogonal directions, and ADC map was calculated. 
 
PET imaging 
FDG-PET scans were conducted, using a PET scanner for 1 patient and a PET/CT scanner for 4 
patients (patient 4’ with Advance; patients 8 - 11 with Discovery ST Elite, GE Healthcare, Waukesha, 
WI, USA). Patients fasted for at least 4 hours prior to the scans. After intravenous administration of 4 
MBq/kg of FDG, patients rested in a waiting room for 30 minutes. Emission scans of the brain were 
conducted for 15 minutes. Resolutions were 2.0 mm × 2.0 mm × 4.25 mm (35 slices) and 2.0 mm × 
2.0 mm ×3.27 mm (47 slices), respectively for the scanners.  
 
Image analysis 
Appearance of the tumors was reviewed with regard to location, size, calcification on CT image 
(present/absent: if present, distribution = diffuse or patchy; density = faint or dense), cystic 
components on T2WI (distribution = diffuse or partial; uniformity = uniform or non-uniform; size = 
small or large) and degree of enhancement on contrast-enhanced T1WI (degree = none to slight or 
moderate to marked, homogeneity = homogeneous or heterogeneous), and categorized by two 
board-certified neuroradiologists in consensus (R.S. and T.K., both had experience in diagnostic 
imaging for 8 years).  
For quantitative analysis, regions of interest (ROIs) were defined independently by two 
neuroradiologists (RS and TK) at different areas (2 to 3 areas) within the tumors of the ADC maps 
and SUV images (ROI size: 50 - 361 mm2 and 114 - 513 mm2, respectively) using a free software 
(MRIcro, http://www.mccauslandcenter.sc.edu/mricro/, provided by Chris Rorden, Neuropsychology 
Lab, Columbia SC, USA). Cares were paid to exclude macroscopic calcifications and cysts on each 
modality referencing to CT image and T2WI. From the values of the ROIs, minimum ADC 
(ADCmin) and maximum SUV (SUVmax) were extracted.  
 
Proliferative activity 
Proliferative activity was measured as MIB-1 LI in formalin-fixed paraffin embedded pathological 
specimens with immuno-histochemical staining using MIB-1 monoclonal antibody. Areas with 
highest number of positive nuclei were identified, and a minimum of 1,000 cells were counted in 
each tissue section (Y.M. a board-certified pathologist majoring in surgical neuropathology). MIB-1 
LI was defined as the percentage of tumor cells which stained positively for Ki-67 nuclear antigen.  
 
Statistical analysis 
Intra-class correlation coefficients (ICCs) for measured values in the ROIs were evaluated. Image 
characteristics were compared between two tumor groups with MIB-1 LI lower to equal to or higher 
than 2% using Fisher’s exact test. ADCmin and SUVmax values were assessed by linear regression 
analyses with values of MIB-1 LI. ROC analysis was conducted to investigate differential capability 
of atypical central neurocytomas from typical ones, when there was a significant correlation. A P 
value less than 0.05 was considered statistically significant. Statistical analyses were conducted using 
commercially available software (MedCalc, version 12.4.0; MedCalc Software, Acacialaan 22, 
B-8400 Ostend, Belgium). 
 
Results 
Characteristics of the patients and tumor images are summarized in Table 1. All of the tumors were 
located in the lateral ventricle and had an attachment to the ventricular wall or septum pellucidum. 
CT scans showed calcifications of variable density and distribution. Almost all tumors had 
heterogeneous appearance with solid portion and cysts that were variable in number and size. MRI 
showed that most tumors were iso- to hypo-intense on T1WI and hyper-intense on T2WI. Contrast 
enhancement of tumors was homogenous or heterogeneous, and degree of enhancement was varied. 
Six tumors showed none to slight enhancement and 5 tumors had moderate to marked enhancement, 
and a tendency that strong enhancement was observed in tumors with higher MIB-1 LI (P = 0.061). 
There was no significant difference in other image characteristics. Fig. 1 shows representative case 
images (patient 10) and Fig. 2 visually summarizes image characteristics.  
The quantitative values of MIB-1 LI, ADCmin and SUVmax are listed in Table 2 and Fig. 3 
shows DWI, ADC map and FDG-PET/CT images of a representative case. MIB-1 LI ranged from 
0.09 to 5.62% (mean ± S.D.: 3.26 ± 1.88%). Four tumors had MIB-1 LI lower than 2%, and eight 
tumors had those higher than 2%. ICCs of the ROI analyses were 0.97 for ADCmin and 0.96 for 
SUVmax, which means excellent agreements. ADCmin values ranged from 0.23 to 1.05 × 10-3 
mm2/s, and significant linear correlation was observed with MIB-1 LI (r = -0.91, P = 0.0006). ROC 
analysis showed that the atypical central neurocytoma could be differentiated from typical one with 
100% sensitivity (95% C.I.: 47.8 - 100.0%) and 100% specificity (39.8 - 100.0%), when the 
threshold value of ADCmin was set at 0.55 × 10-3 mm2/s (P < 0.0001). The SUVmax ranged from 
3.35 to 7.61. The values had high correlation with MIB-1 LI (r = 0.74), but it was not significant (P = 
0.15). These linear relationships are presented in Fig. 4.  
 
Discussion 
Although the central neurocytoma has been considered indolent, there are some cases that showed 
aggressive biologic behavior including postoperative rapid regrowth (19, 20). Among many 
pathologic features, elevated MIB-1 LI correlates with an increased recurrence rate and poor 
outcome (5, 21) and is thought to be a reliable immune-histopathologic marker (5). No significant 
correlation was found between other histopathologic characteristics and clinical outcome (22, 23). In 
this study, large variety was observed in calcification and cystic changes, and only strong 
enhancement suggested increased proliferative potential as in the former case reports (24, 25).  
Our result of MIB-1 LI is congruent with the previous reports ranging less than 0.1 to 11.2% 
(5, 21, 23). There was a significant negative linear correlation between MIB-1 LI and ADCmin as 
was in other type of brain tumors (13). ADC value has an inverse relation with tumor grades (10, 26), 
and poor survival was reported in malignant glial tumors with lower ADCmin (14, 27). Our result 
indicates that lower ADCmin reflects malignant potential of the central neurocytoma. In case patient 
4, the tumor had a high MIB-1 LI (5.62%) with a lower ADCmin (0.45 × 10-3 mm2/s) than the 
proposed threshold. After partial resection, the tumor regrew gradually in three-year follow up 
(patient 4’). The recurrent tumor showed a high SUVmax (7.61) before second operation, and the 
pathologic specimen revealed that tumor maintained high proliferative activity (MIB-1 LI = 4.68%).  
Increased glucose metabolism indicates higher proliferative activity of the brain tumor (28). 
Our study presented high linearity between SUVmax and MIB-1 LI. This result may help to facilitate 
the usage of FDG-PET examinations in the central neurocytoma as in a previous case report which 
demonstrated that a central neurocytoma with higher FDG uptake showed an increased proliferative 
index associated with atypical histological features (18). 
There are several limitations in this study. First, the number of cases is small. However, it is 
considered inevitable, because the central neurocytoma is relatively rare. Because of this rarity, the 
enrollment period was very long. Therefore second, not all image examinations were available, and 
different scanners and parameters were used particularly in MR Imaging.  
In conclusion, central neurocytomas had a variety of image appearances, and there was no significant 
correlation with MIB-1 LI except a tendency that central neurocytomas with higher MIB-1 LI 
demonstrated stronger enhancement. Assessment of proliferative potential would be difficult if only 
morphological aspects are considered. ADCmin showed significant linear correlation with MIB-1 LI, 
and SUVmax had the same tendency. Both quantitative imaging values of ADCmin and SUVmax, 
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Table 1. Characteristics of the patients and tumor images 
Patient  
No. 
Sex / Age (yr) Location Size 
(mm) 
Calcification on CT 
distribution / density 
Cystic appearance on T2WI 
distribution / uniformity / size 
Enhancement on Gd-T1WI 
degree / homogeneity 
1 M/31 LtLV~3V 54 × 43 diffuse / dense diffuse / non-uniform / large  none / n.a. 
2 F/34 RtLV 61 × 39 patchy / dense diffuse / non-uniform / large  n.a. / n.a. 
3 M/35 RtLV 39 × 18 none diffuse / uniform / small  none / n.a. 
4 F/21 RtLV 42 × 37 patchy / faint partial / non-uniform / small  marked / heterogeneous 
4’ F/24 RtLV 27 × 20 none partial / uniform / small  marked / homogeneous 
5 F/38 LtLV 39 × 25 patchy / dense diffuse / non-uniform / large  slight / homogeneous 
6 F/54 LtLV 63 × 44 none partial / non-uniform / large  marked / homogeneous 
7 M/22 LtLV~3V 59 × 40 patchy / faint diffuse / non-uniform / small  none / n.a. 
8 M/28 LtLV 27 × 19 none partial / uniform / small  moderate / heterogeneous 
9 M/34 RtLV 29 × 25 patchy / faint diffuse / non-uniform / large  none / n.a. 
10 M/34 LtLV 21 × 17 none diffuse / uniform / small  moderate / homogeneous 
11 M/26 LtLV 15 × 13 none partial / uniform / small  none / n.a. 
LtLV: left lateral ventricle, RtLV: right lateral ventricle, 3V: third ventricle, n.a.: not applicable, 
Gd-T1WI: Gadolinium-enhanced T1WI 
Table 2. MIB-1 LI, ADCmin and SUVmax of the central neurocytomas 
Patient No. MIB-1 LI (%) ADCmin (10-3 mm2/s) SUVmax  
1 0.77 0.92 n.a. 
2 5.42 n.a. n.a. 
3 0.09 0.95 n.a. 
4 5.62 0.45 n.a. 
4’ 4.68 n.a. 7.61 
5 1.15 1.05 n.a. 
6 3.03 n.a. n.a. 
7 1.98 0.73 n.a. 
8 3.95 0.45 5.60 
9 3.28 0.55 3.35 
10 4.12 0.26 4.55 
11 5.03 0.23 5.61 
MIB-1 LI: MIB-1 labeling index, ADCmin: minimum value of ADC in the tumor ROI, SUVmax: 









Figure 1. A representative case of a central neurocytoma located at the left lateral ventricle (patient 
10). Diffusely distributed small cysts on T2WI (A) and moderately enhanced solid portion on 
contrast-enhanced T1WI (B) are noted. Calcification is not identified on CT (C).  
 
 Figure 2. Box plots show the relationship of MIB-1 LI values with the following image 
characteristics: (A) calcification on CT (none or present, patchy or diffuse, and dense or faint), (B) 
cysts on T2WI (diffuse or partial, uniform or non-uniform, and small or large), and (C) contrast 
enhancement on T1WI (none to slight or moderate to marked, and homogeneous or heterogeneous). 
Image characteristics of tumors varies greatly and only the difference in contrast enhancement 
between none to slight and moderate to marked is marginally significant (P = 0.061) between tumors 
with MIB-1 LI lower or higher than 2% using Fisher’s exact test.  
 Figure 3. The solid portion of the tumor in the representative case shows high signal on DWI (A) and 
restricted diffusion on ADC map, where a ROI for ADCmin is drawn (B). A ROI for SUVmax is 
defined at the same location on FDG-PET (C), referring to simultaneously acquired CT image (D).  
 Figure 4. (A) Linear regression analyses shows significant negative correlation (r = -0.9) between 
ADCmin and MIB-1 LI (P = 0.0006). (B) There is high correlation between SUVmax and MIB-1 LI 
(r = 0.74), but it is not statistically significant (P = 0.15). 
